Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010

You may also be interested in...



Astellas Submits Pediatric Data To U.S. FDA For Flomax Exclusivity; Announces JV With Maxygen

TOKYO - Astellas Pharma July 1 said its U.S. licensee for Flomax (tamsulosin), Boehringer Ingelheim Pharmaceuticals submitted data to U.S. FDA from a study on pediatric patients with neurogenic bladders - apparently to fend off generics offerings when the drug's patent protection expires later this year

Astellas, Boehringer Sue Impax For Prostate Drug Patent Infringement

TOKYO - Moving in concert with the Japanese government's policy to toughen intellectual property rights protection, Astellas, jointly with Boehringer Ingelheim Pharmaceuticals, filed a patent infringement lawsuit in the United States against Impax Laboratories for Astellas' prostate treatment drug, the company announced July 22

Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year

NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel